CN1646123A - 胃食物容纳障碍治疗剂 - Google Patents

胃食物容纳障碍治疗剂 Download PDF

Info

Publication number
CN1646123A
CN1646123A CNA038079755A CN03807975A CN1646123A CN 1646123 A CN1646123 A CN 1646123A CN A038079755 A CNA038079755 A CN A038079755A CN 03807975 A CN03807975 A CN 03807975A CN 1646123 A CN1646123 A CN 1646123A
Authority
CN
China
Prior art keywords
acid addition
addition salt
general formula
thiazolyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038079755A
Other languages
English (en)
Chinese (zh)
Inventor
松永勇吾
上木茂
东野雷太
河内雅直
加藤博树
小林四郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28786350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1646123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Priority to CN201010611741.5A priority Critical patent/CN102125551B/zh
Publication of CN1646123A publication Critical patent/CN1646123A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038079755A 2002-04-08 2003-04-08 胃食物容纳障碍治疗剂 Pending CN1646123A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201010611741.5A CN102125551B (zh) 2002-04-08 2003-04-08 胃容纳障碍治疗剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP104894/2002 2002-04-08
JP2002104894 2002-04-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010611741.5A Division CN102125551B (zh) 2002-04-08 2003-04-08 胃容纳障碍治疗剂

Publications (1)

Publication Number Publication Date
CN1646123A true CN1646123A (zh) 2005-07-27

Family

ID=28786350

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038079755A Pending CN1646123A (zh) 2002-04-08 2003-04-08 胃食物容纳障碍治疗剂
CN201010611741.5A Expired - Lifetime CN102125551B (zh) 2002-04-08 2003-04-08 胃容纳障碍治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010611741.5A Expired - Lifetime CN102125551B (zh) 2002-04-08 2003-04-08 胃容纳障碍治疗剂

Country Status (14)

Country Link
US (4) US20050176788A1 (https=)
EP (2) EP2301540A1 (https=)
JP (2) JP5281226B2 (https=)
KR (4) KR20050002925A (https=)
CN (2) CN1646123A (https=)
AT (1) ATE522214T1 (https=)
AU (1) AU2003236326B2 (https=)
CA (1) CA2481916C (https=)
CY (1) CY1112057T1 (https=)
DK (1) DK1493441T3 (https=)
ES (1) ES2368732T3 (https=)
PT (1) PT1493441E (https=)
SI (1) SI1493441T1 (https=)
WO (1) WO2003084537A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315225A (zh) * 2014-07-07 2016-02-10 中美华世通生物医药科技（武汉）有限公司 阿考替胺的酸加成盐及其制备方法
CN109988121A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447612A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 阿考替胺水合物晶型及其制备方法和用途
CN103980226A (zh) * 2014-05-10 2014-08-13 杭州新博思生物医药有限公司 盐酸阿考替胺水合物晶型及其制备方法
CN104045606B (zh) * 2014-07-11 2015-09-30 杭州新博思生物医药有限公司 一锅法制备阿考替胺盐酸盐的方法
WO2023288254A1 (en) 2021-07-14 2023-01-19 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219747C (en) * 1995-05-18 2008-11-25 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivative, medicament containing the same, and intermediate for preparation of said compound
JPH10212271A (ja) * 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
ES2198719T3 (es) * 1997-06-24 2004-02-01 Zeria Pharmaceutical Co., Ltd. Procedimiento de produccion de los derivados de 2-hidroxibenzamida.
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
KR20010080025A (ko) * 1998-11-23 2001-08-22 디르크 반테 소화불량 치료용 의약의 제조를 위한 프루칼로프라이드의용도
EE04780B1 (et) * 1999-06-02 2007-02-15 Janssen Pharmaceutica N.V. Aminoalküül-asendatud bensodioksaani, bensofuraani või bensopüraani derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja selle valmistamismeetod
AU782648B2 (en) * 1999-11-23 2005-08-18 Janssen Pharmaceutica N.V. Use of 5HT3 agonists for relaxing the fundus
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
AU5668501A (en) * 2000-09-08 2002-03-22 Zeria Pharm Co Ltd Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions
US6986882B2 (en) * 2002-01-17 2006-01-17 Astrazeneca Ab Therapy for functional dyspepsia

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315225A (zh) * 2014-07-07 2016-02-10 中美华世通生物医药科技（武汉）有限公司 阿考替胺的酸加成盐及其制备方法
CN109988121A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法

Also Published As

Publication number Publication date
CN102125551A (zh) 2011-07-20
US20200375954A1 (en) 2020-12-03
CY1112057T1 (el) 2015-11-04
EP1493441A4 (en) 2007-10-17
EP1493441A1 (en) 2005-01-05
US20150141475A1 (en) 2015-05-21
US20090156652A1 (en) 2009-06-18
ES2368732T3 (es) 2011-11-21
WO2003084537A1 (en) 2003-10-16
CA2481916C (en) 2013-02-26
PT1493441E (pt) 2011-09-28
JPWO2003084537A1 (ja) 2005-08-11
JP5360075B2 (ja) 2013-12-04
EP2301540A1 (en) 2011-03-30
AU2003236326A1 (en) 2003-10-20
KR101423284B1 (ko) 2014-07-24
KR20110010837A (ko) 2011-02-07
CN102125551B (zh) 2015-07-22
DK1493441T3 (da) 2011-10-17
JP2011068692A (ja) 2011-04-07
JP5281226B2 (ja) 2013-09-04
CA2481916A1 (en) 2003-10-16
ATE522214T1 (de) 2011-09-15
EP1493441B1 (en) 2011-08-31
AU2003236326B2 (en) 2008-02-28
KR20130101162A (ko) 2013-09-12
KR20050002925A (ko) 2005-01-10
US20050176788A1 (en) 2005-08-11
SI1493441T1 (sl) 2011-12-30
KR20120037035A (ko) 2012-04-18

Similar Documents

Publication Publication Date Title
US20200375954A1 (en) Therapeutic agent for food competence disorder in stomach
CN1236770C (zh) 胃酸分泌抑制组合物
JP4415075B2 (ja) 炎症性腸疾患のためのカッパーアヘン製剤作働薬
WO2013149148A2 (en) Dosage forms of halofuginone and methods of use
JP4876367B2 (ja) アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤
AU2001256685A1 (en) Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions
CN1230178C (zh) 伴有前列腺肥大症的膀胱刺激症状治疗药
JP2005533829A (ja) 機能性腸疾患の処置における４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ［２，３−ｄ］ピリミジン
CN115768430A (zh) 伴随代谢异常的疾病或综合征中的肌力下降症状的改善剂或预防剂
JP4598674B2 (ja) 統合失調症治療剤
WO2025163534A1 (en) Crystal form of a peptide inhibitor of interleukin-23 receptor
CN1165000A (zh) 缓解由缺血引起的组织损伤的方法
JP5142991B2 (ja) １−（３−クロロフェニル）−３−アルキルピペラジンを含む食欲障害治療用医薬組成物
JP2021172639A (ja) 医薬組成物
HK1106701A (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
WO2000028984A1 (fr) Remedes agissant contre un trouble fonctionnel du tractus digestif
HK1115807A (en) Gastrointestinal motor activation regulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050727